CLINICAL TRIAL: BOSENTAN IN PATIENTS WITH SYMPTOMATIC PULMONARY HYPERTENSION & S

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项随机、安慰剂对照的多中心IIIb期研究，旨在评估波生坦(125 mg，2次/d)在右心导管术确诊的镰状细胞病合并肺动脉高压患者中的安全性和有效性。总共将有78名患者入选。这项研究将在美国、英国、法国和荷兰的大约24个中心进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, placebo-controlled, multicenter, Phase IIIb study designed to assess the safety and efficacy of Bosentan (125 mg BID) in sickle cell disease patients with pulmonary arterial hypertension confirmed by right-heart catheterization. A total of 78 patients will be enrolled. The study will be conducted in approximately 24 centers in the US, the UK, France, and the Netherlands.